Disseminated Histoplasmosis in HIV-Infected Patients in South America: A Neglected Killer Continues on Its Rampage

Mathieu Nacher1,2, Antoine Adenis1,2, Sigrid Mc Donald3, Margarete Do Socorro Mendonca Gomes4, Shanti Singh5, Ivina Lopes Lima6, Rosilene Malcher Leite6, Sandra Hermelijn3, Merrill Wongsokario6, Marja Van Eer7, Silvia Marques Da Silva8, Maurimelia Mesquita Da Costa8, Marizette Silva9, Maria Calvacante9, Terezinha do Menino Jesus Silva Leitao10, Beatriz L. Gómez11, Angela Restrepo11, Angelo Tobon11, Cristina E. Canteros12, Christine Aznar2, Denis Blanchet2, Vincent Vantilcke13, Cyrille Vautrin13, Rachida Boukhari13, Tom Chiller14, Christina Scheel14, Angela Ahlquist14, Monika Roy14, Olivier Lortholary15,16, Bernard Carme1,2, Pierre Couppe2, Stephen Vreden3

1 Centre d’Investigation Clinique Épidémiologie Clinique Antilles Guyane (Inserm/DGOS CIE 802), Centre Hospitalier de Cayenne, Cayenne, French Guiana, France,
2 Epidemiologie Parasitoses et Mycoses Tropicales, EA 3593, Université Antilles Guyane, Cayenne, French Guiana, France,
3 Academisch Ziekenhuis Paramaribo Hospital, Paramaribo, Suriname,
4 Laboratório Central de Saúde Pública do Amapá, Macapa, Brazil,
5 National AIDS Program, Georgetown, Guyana,
6 Public Health Central Laboratory of Suriname, Paramaribo, Suriname,
7 Diakonessenhuis Hospital, Paramaribo, Suriname,
8 Instituto Evandro Chagas, Belém, Brazil,
9 Hospital de Clinicas Dr. Alberto Lima, Macapa, Brazil,
10 Universidade Federal do Ceará, Faculdade de Medicina, Departamento de Saúde Comunitaria, Fortaleza, Ceará, Brazil,
11 Corporación para Investigaciones Biológicas, Medellín, Colombia,
12 INEI-ANLIS Dr. Carlos G. Malbran, Buenos Aires, Argentina,
13 Centre Hospitalier de l’Ouest Guyanais, Saint Laurent du Maroni, French Guiana, France,
14 Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia,
15 United States of America,
16 CNRS URA3012, Paris, France

HIV/AIDS is not a neglected disease. Histoplasmosis is not considered a neglected disease in North America. However, in South America, it should be. It often affects neglected populations and represents a lethal blind spot of the HIV/AIDS data collection systems. Counts of new AIDS cases and AIDS-related deaths are useful to follow the epidemic; however, they overlook the exact cause of death. In the context of the South American pathogen ecology, the systemic mycosis due to *Histoplasma capsulatum* var. *capsulatum* is probably on the top of the list of AIDS-defining illnesses and AIDS-related deaths [1], yet it is mostly undiagnosed and is not even on the diagnostic algorithm used by a significant proportion of clinicians facing a febrile, severely immunodepressed patient in the region.

The Invisible Burden

Studies performed in the 1950s and 1960s on the histoplasmin skin test positivity in South America showed positivity rates around 30% from Trinidad and Tobago in the North, to Uruguay and Argentina in the South. The pathogen is there [2]. Despite this, expertise and awareness of this disease is limited to mycologists and some clinical teams scattered throughout the South American continent [2–16]. But those with expertise are the exception rather than the rule. Imported cases in Europe occurring in HIV-infected residents or travellers from South America, notably in France, Spain, and Italy, are starting to be recognized, but often late in the course of the disease because clinicians are not familiar with this “endemic” disease [17–19].

For too long, the absence of a simple, reliable, and affordable diagnostic test has made it difficult to determine the burden of this disease in HIV-infected patients in much of South America. The gold standard for diagnosis relies, so far, on the culture of fluid and tissue samples [20]. This requires invasive investigations by clinicians (bone marrow aspirates; biopsies of the liver, lymph node, and intestine; etc.). From the lab perspective, direct examination may accelerate diagnosis, but culture may take weeks and require a BSL 2 laboratory. Detection of specific antigens in serum or urine samples is not available for diagnosis in most of South America, and galactomannan detection (cross reactivity during histoplasmosis) is not being used as a standard of care. Contact with clinicians from various countries suggests that, although severe histoplasmosis often kills in a few days, most clinicians are not very aggressive in their investigations. Moreover, presumptive antifungal therapy is rare. Biopsies are usually immersed in formalin by surgeons rather than sent for culture. Most often, clinicians do not take proper samples for mycological diagnosis, creating a vicious cycle that diminishes the capacity of mycological laboratories and perpetuates under-funding and the absence of diagnosis and, thus, the “nonexistence” of the very disease that is killing numerous patients.

In French Guiana, there has been a mycology laboratory since 1997 with a BSL 3 laboratory. The virtuous cycle between laboratory and clinicians has been fruitful: clinicians are well informed about histoplasmosis and are quite aggressive in looking for the infection, while the mycology laboratory has the capacity to appropriately process and identify *Histoplasma* in clinical specimens [21]. Although published maps [2] show no histoplasmosis in most of French Guiana, the recent
figures that have emerged are striking. With 1.5 cases per 100 patient-years, histoplasmosis is the most common cause of AIDS-defining illness. Interestingly, despite awareness of this disease and availability of liposomal amphotericin B, it has also been the leading cause of AIDS-related death for decades. A recent 2-year study of all HIV patients admitted in Saint Laurent du Maroni hospital showed that 41% of admitted patients with CD4 counts below 200 had disseminated histoplasmosis, and 85% of admitted patients with CD4 counts below 50 and isolated fever had disseminated histoplasmosis. This is a clear message for physicians when admitting a severely immunodepressed HIV patient in the region: “Don’t miss histoplasmosis!”

No Data = No Existence. Meanwhile, Patients Continue Dying from a Treatable Disease...

The high prevalence of HIV-Histoplasma coinfections on the South American continent is not a trivial problem. The scarcity of the published research on this topic reflects the tragic fact that this problem is evolving under the radar of healthcare systems and is truly a neglected problem. The high prevalence of HIV-Histoplasma coinfections is not. The sooner we do it, the better for our patients.

We Need Research and We Need to Act Now

The HIV/AIDS epidemic is still active in countries in the Amazon basin. Guyana, Suriname, French Guiana, and the Brazilian state of Amapa all have HIV prevalence rates over 1% of the population. Although the AIDS incidence has steadily declined in the southern states of Brazil, the situation in the northern (Amazonas, Roraima, and Amapa) and the northeastern states of Brazil is still concerning. A very coarse calculation based on 600,000 HIV patients and an annual histoplasmosis incidence rate of 1.5% would estimate the annual number of cases to be in the thousands. Unfortunately, histoplasmosis thus still has a future in HIV patients. Although there is a need for epidemiologic research to measure the true burden of disease in various regions of South America, actions can, and should, be taken to diagnose and treat patients now. We need to develop standard mycological practices in the area that emphasize early and aggressive clinical diagnosis, and we need to develop new rapid diagnostic tools and advocate for affordable treatment. New affordable diagnostic assays (CDC, Immy) are presently being tested in Brazil, French Guiana, Suriname, and Colombia. We hope they will allow us to improve our knowledge of local epidemiologies and reduce patient mortality through early diagnosis and increased awareness. Although amphotericin B is available, it has potential significant renal side effects. Liposomal amphotericin B is the treatment of choice of the most severe cases of HIV-associated histoplasmosis, but its cost exceeds 800 US dollars per day. Gilead Sciences, Inc. has committed to the procurement of HIV drugs at affordable prices. Extending this policy to the problem of treating HIV-associated histoplasmosis, a neglected disease, would be an important step in improving the health of HIV/AIDS patients in the region. In the near future, DNDI (Drugs for Neglected Diseases initiative) should provide a low-cost, heat-stable alternative to liposomal amphotericin B that could be valuable for histoplasmosis treatment. Our focus has been HIV-associated disseminated histoplasmosis; however, it should be emphasized that the problem of missing the diagnosis of histoplasmosis in South America also extends to some immunocompetent patients or patients with causes of immunodepression other than HIV [22].

We need tests; we need treatments; but first of all, we physicians need to integrate our South American epidemiology in our diagnostic algorithms. Looking for malaria in febrile patients in malaria-endemic areas is automatic; looking for histoplasmosis in febrile, immunosuppressed, HIV-infected patients in South America, Central America, and perhaps way beyond [23,24], is not. The sooner we do it, the better for our patients.

References


